ArticleDiscover oncology2025
Identification of key biomarkers and potential therapeutic drugs in nasopharyngeal carcinoma based on comprehensive bioinformatics analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nasopharyngeal carcinoma (NPC) is the most prevalent type of head- and -neck cancer, and its diagnosis and treatment are currently facing significant challenges. This study aimed to identify biomarkers associated with NPC by performing bioinformatic analysis on the GSE12452, GSE53819, and GSE64634 datasets from the GEO database. First, differentially expressed genes (DEGs) between NPC and normal nasopharyngeal tissues were screened. Then, these DEGs were subjected to RobustRank Aggregation analysis. Through Receiver Operating Characteristic (ROC) analysis and three machine-learning models, biomarkers such as DNAH5, ZMYND10, LRRC6, ARMC4, DNAI2, and DNALI1 were identified. Enrichment analysis was performed to uncover the common pathways of these biomarkers. Using the Comparative Toxicogenomics Database (CTD), target drugs for NPC were predicted based on these biomarkers. Additionally, immune infiltration analysis was carried out to study the relationship between these biomarkers and immune cells. A regulatory network was also constructed. It was found that these biomarkers are mainly involved in cytokine-cytokine receptor interaction, and some are part of common cancer-related signaling pathways. In addition, quantitative real time polymerase chain reaction (qRT-PCR) results showed that the expression levels of all biomarkers were significantly elevated in normal cell samples. DNAH5 and ZMYND10 were significantly higher in normal surrounding tissues. These findings provided potential support for the early clinical diagnosis and treatment of nasopharyngeal carcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.